Spravato® is a nasal spray that contains esketamine, which originates from a specific part of the ketamine molecule.
Depression causes a drop in communication across different brain regions, leading to symptoms such as persistent negative thoughts, cognitive impairments, and feelings of despair. However, Spravato® targets glutamate, a neurotransmitter that helps brain cells develop new communication pathways.
Spravato® is approved by the Food and Drug Administration (FDA) to treat major depressive disorder (depression).
In 4 weeks,
52.5% of patients achieved full remission, with a higher percentage that had a significant improvement!